Literature DB >> 3339184

Effects of clofilium on ischemic subendocardial Purkinje fibers 1 day postinfarction.

W B Gough1, D Hu, N el-Sherif.   

Abstract

One day after ligation of the canine anterior descending coronary artery, clofilium, a long-acting class III antiarrhythmic agent, was studied for its effects on normal and ischemic Purkinje fibers. In normal Tyrode's solution (4 mM potassium, 2.7 mM calcium) clofilium (10(-7) to 10(-5) M) increased action potential duration. Although only 2 of 10 normal Purkinje fibers developed early after depolarizations and early afterdepolarization-initiated triggered activity, 10 of 11 ischemic Purkinje fibers developed these features. Consequently, action potentials in ischemic fibers were prolonged to durations greater than 10 s. The triggered activity in the ischemic Purkinje fibers produced repetitive activity in adjacent normal ventricular muscle. In vivo, 3 days after ligation, the administration of 3 to 10 mg/kg clofilium induced grouped beating. Action potentials recorded subsequently from these same hearts in vitro showed early afterdepolarizations, triggered activity and a similar grouping of responses. Therefore, clofilium differentially produced early afterdepolarizations in ischemic Purkinje fibers. This is a mechanism by which clofilium could be arrhythmogenic in an ischemic heart.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339184     DOI: 10.1016/0735-1097(88)90112-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  2 in total

1.  Antifibrillatory effects of clofilium in the rabbit isolated heart.

Authors:  G S Friedrichs; L Chi; A L Green; B R Lucchesi
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

2.  Purkinje Cells as Sources of Arrhythmias in Long QT Syndrome Type 3.

Authors:  Vivek Iyer; Danilo Roman-Campos; Kevin J Sampson; Guoxin Kang; Glenn I Fishman; Robert S Kass
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.